|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Sagent_Pharmaceuticals
gptkb:Mallinckrodt_Pharmaceuticals
gptkb:Questcor_Pharmaceuticals
gptkb:Therakos
gptkb:Therakos,_Inc.
2017
Civitas Therapeutics
|
|
gptkbp:businessModel
|
distribution
research and development
manufacturing
marketing
regulatory compliance
sales
clinical trials
pharmaceutical development
post-market surveillance
product launch
|
|
gptkbp:caseTypes
|
Chapter_11
|
|
gptkbp:CEO
|
gptkb:Mark_Trudeau
2015
2015-present
|
|
gptkbp:context
|
opioid crisis
|
|
gptkbp:employees
|
approximately 3,000
|
|
gptkbp:filingCountry
|
2020
|
|
gptkbp:focus
|
rare diseases
autoimmune diseases
pain management
|
|
gptkbp:focus_area
|
specialty pharmaceuticals
|
|
gptkbp:founded
|
1867
|
|
gptkbp:headquarters
|
gptkb:Dublin
gptkb:Dublin,_Ireland
gptkb:Ireland
corporate office
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mallinckrodt plc
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:market
|
gptkb:United_States
$1.2 billion (2021)
|
|
gptkbp:notableEvent
|
gptkb:Inomax
gptkb:Xyrem
gptkb:H.P._Acthar_Gel
gptkb:Ofirmev
Acthar Gel
|
|
gptkbp:previousName
|
gptkb:Mallinckrodt,_Inc.
|
|
gptkbp:products
|
specialty pharmaceuticals
|
|
gptkbp:revenue
|
2020
annual
$2.5 billion (2020)
|
|
gptkbp:sells
|
gptkb:NYSE
|
|
gptkbp:stockExchange
|
gptkb:NYSE
|
|
gptkbp:subsidiary
|
gptkb:Mallinckrodt_Pharmaceuticals
|
|
gptkbp:website
|
www.mallinckrodt.com
|